Getein Biotech(SH:603387)2023-04-26 16:00Financial Performance - In 2022, the company achieved a net profit of RMB 503,944,698.54, with a net profit attributable to shareholders of RMB 498,909,980.40[6]. - The company proposed a cash dividend of RMB 3 per 10 shares, amounting to a total cash dividend of RMB 152,146,055.10, which represents 30.50% of the net profit attributable to shareholders[7]. - The total distributable profit for 2022 was RMB 1,454,947,989.25, after accounting for the profit distribution and retained earnings[6]. - The parent company reported a net profit of RMB 433,531,627.04 for 2022, with a total distributable profit of RMB 1,228,815,194.65[6]. - The company's operating revenue for 2022 reached ¥1,821,860,703.15, representing a year-on-year increase of 29.97%[25]. - The net profit attributable to shareholders for 2022 was ¥498,909,980.40, up 25.04% compared to the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 25.59% to ¥461,538,014.58[25]. - Basic earnings per share for 2022 were ¥0.98, an increase of 24.05% from ¥0.79 in 2021[26]. - The weighted average return on equity for 2022 was 21.76%, up from 20.43% in 2021[26]. - Total assets at the end of 2022 amounted to ¥3,677,437,948.24, reflecting a year-on-year growth of 17.19%[25]. Risk Management and Compliance - The company has outlined various risk factors that may affect its future development strategies and operational goals[10]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[4]. - The company received a standard unqualified audit report from Zhongtian Yun Accounting Firm[5]. Research and Development - The company achieved a research and development investment of 26,205.90 million yuan, a year-on-year increase of 40.19%, accounting for 14.38% of operating revenue[49]. - The number of R&D personnel increased to 632, up by 184 from the beginning of 2022[49]. - The company has 500 valid patents as of December 31, 2022, with 310 authorized patents, including 30 invention patents[49]. - The company has developed eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular diagnostics, enhancing its product system from single POCT products to a diverse range[70]. - The company is committed to continuous innovation in product development, focusing on unmet clinical needs[50]. Product Development and Market Expansion - The company launched several new products, including the MAGICL6200 fully automated chemiluminescence analyzer (400T/H) and the CM1000 fully automated biochemical analyzer (1000T/H)[50]. - The company launched the Metis600 emergency blood cell line, which integrates multiple testing capabilities for clinical needs, including blood routine, inflammation, cardiovascular, and glycation tests[40]. - The company is focusing on expanding its market share in grade hospitals by increasing penetration in previously untapped departments[38]. - The company has expanded its chemiluminescence product line to 78 items, including 11 cardiovascular projects, maintaining a leading position in the market[44]. - The company aims to further develop its product offerings in areas such as coagulation series and liver cancer screening, enhancing its competitive edge in the chemiluminescence market[46]. Marketing and Sales Strategy - The company implemented a dual-driven marketing reform strategy focusing on "core" and "collaboration" to enhance growth[52]. - The company has established a comprehensive after-sales service system with over 200 frontline engineers and 30 technical engineers nationwide[59]. - The company is focusing on proactive maintenance and upgrades for large instruments to improve customer satisfaction[59]. - The company aims to leverage new policies to enhance the construction of county-level medical institutions, benefiting the IVD sector[66]. - The company is focusing on expanding its direct sales team to enhance customer loyalty and market barriers[81]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[153]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to oversee financial conditions and major matters[154]. - The company has established a robust information disclosure system, ensuring timely and accurate communication of significant information to shareholders[155]. - The company maintains independent operations with complete assets, personnel, and financial systems, ensuring no conflicts of interest with controlling shareholders[156]. - The company has conducted 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders and no rejected resolutions[159]. Employee and Management Practices - The company has established a comprehensive welfare system for employees, including various benefits to enhance employee satisfaction and belonging[184]. - The company conducted training programs focusing on R&D processes, safety production, and management talent development during the reporting period[185]. - The company’s remuneration policy aims to align employee development with corporate interests, ensuring fair and competitive compensation[184]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0898 million yuan[170]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[167]. - The company plans to invest 200 million RMB in marketing to support the launch of new products and enhance brand visibility[167]. - The company aims to establish wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa to deepen local market penetration[143]. - The company plans to increase R&D investment and strengthen technological innovation to enhance core competitiveness and improve operational performance[151].